Charged Ion Channel Blockers for Selective Nociceptor Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain, itch, and neurogenic inflammation treatments lack selective inhibitors that can target sensory neurons without affecting non-nociceptive neurons, leading to unwanted side effects such as general numbness and paralysis.
Innovation Solution
Development of quaternary ammonium compounds that selectively inhibit pain, cough, and itch-sensing neurons by entering through large pore receptor/ion channels, such as TRPV1, TRPA1, TRPM8, ASIC, and P2X, while minimizing effects on other cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If local anesthetics are used to block sodium channels in neurons, then pain transmission is blocked, but general numbness and motor deficits occur due to block of non-nociceptive neurons
Solution Approach 1:
The patent applies local quality by designing compounds with specific properties (small size, cationic charge) that enable selective entry into nociceptors through TRPV1 channels. This selectivity ensures that only pain-sensing neurons are affected, while other neuron types remain functional, thereby achieving pain blockade without general numbness or motor deficits
Solution Approach 2:
The patent utilizes parameter changes by exploiting the unique biophysical properties of TRPV1 channels (large pore size when activated) to allow passage of charged compounds that cannot cross intact membranes. This parameter-based selection mechanism enables differential entry into nociceptors versus other neurons, resolving the contradiction between effective pain blockade and avoidance of side effects
2Reliability
If charged derivatives of local anesthetics are used, then selectivity for nociceptors improves, but membrane permeability is lost
Solution Approach 1:
The patent employs TRPV1 channels as intermediaries to deliver charged compounds into nociceptors. The activated TRPV1 channel serves as a temporary conduit that allows passage of cationic molecules that would otherwise be membrane-impermeable. This intermediary mechanism resolves the contradiction by providing a selective entry route that bypasses the need for direct membrane penetration
Solution Approach 2:
The patent applies preliminary action by requiring activation of TRPV1 channels (through noxious stimuli or agonists) before the charged compound can enter the cell. This preliminary activation creates the necessary condition (open channel) that enables subsequent compound entry, thereby allowing charged compounds to achieve nociceptor selectivity without requiring inherent membrane permeability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat pain, itch, and neurogenic inflammation by selectively blocking ion channels in nociceptors and pruriceptors, reducing neurogenic inflammation and minimizing side effects on non-nociceptive neurons.
Implementation Method 1
small, cationic drug molecules gain access to the intracellular compartment of sensory neurons via entry through large pore receptor/ion channels
Implementation Method 2
These anesthetics block sodium channels and thereby the excitability of all neurons
Data Source
AI summary
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.